Your browser doesn't support javascript.
loading
Molecular characterization of CNS paragangliomas identifies cauda equina paragangliomas as a distinct tumor entity.
Schweizer, Leonille; Thierfelder, Felix; Thomas, Christian; Soschinski, Patrick; Suwala, Abigail; Stichel, Damian; Wefers, Annika K; Wessels, Lars; Misch, Martin; Kim, Hee-Yeong; Jödicke, Ruben; Teichmann, Daniel; Kaul, David; Kahn, Johannes; Bockmayr, Michael; Hasselblatt, Martin; Younsi, Alexander; Unterberg, Andreas; Knie, Bettina; Walter, Jan; Al Safatli, Diaa; May, Sven-Axel; Jödicke, Andreas; Ntoulias, Georgios; Moskopp, Dag; Vajkoczy, Peter; Heppner, Frank L; Capper, David; Hartmann, Wolfgang; Hartmann, Christian; von Deimling, Andreas; Reuss, David E; Schöler, Anne; Koch, Arend.
Afiliación
  • Schweizer L; Department of Neuropathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany. leonille.schweizer@charite.de.
  • Thierfelder F; German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany. leonille.schweizer@charite.de.
  • Thomas C; Department of Neuropathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
  • Soschinski P; German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Suwala A; Institute of Neuropathology, University Hospital Münster, Pottkamp 2, Münster, Germany.
  • Stichel D; Institute of Neuropathology, University Hospital Münster, Pottkamp 2, Münster, Germany.
  • Wefers AK; Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Wessels L; Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.
  • Misch M; Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Kim HY; Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.
  • Jödicke R; Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Teichmann D; Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.
  • Kaul D; Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
  • Kahn J; Department of Neurosurgery, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Bockmayr M; Department of Neurosurgery, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Hasselblatt M; Department of Neuropathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
  • Younsi A; German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Unterberg A; Department of Neuropathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
  • Knie B; Department of Neuropathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
  • Walter J; Department of Radiation Oncology and Radiotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Al Safatli D; Department of Radiology, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • May SA; Department of Pathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin, Germany.
  • Jödicke A; Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Ntoulias G; Research Institute Children's Cancer Center Hamburg, Hamburg, Germany.
  • Moskopp D; Institute of Neuropathology, University Hospital Münster, Pottkamp 2, Münster, Germany.
  • Vajkoczy P; Department of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany.
  • Heppner FL; Department of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany.
  • Capper D; Department of Neurosurgery, Vivantes Klinikum Im Friedrichshain, Berlin, Germany.
  • Hartmann W; Department of Neurosurgery, Universitätsklinikum Jena, Jena, Germany.
  • Hartmann C; Department of Neurosurgery, Universitätsklinikum Jena, Jena, Germany.
  • von Deimling A; Department of Neurosurgery, Klinikum Chemnitz, Chemnitz, Germany.
  • Reuss DE; Department of Neurosurgery, Vivantes Klinikum Neukölln, Berlin, Germany.
  • Schöler A; Department of Neurosurgery, Vivantes Klinikum Neukölln, Berlin, Germany.
  • Koch A; Department of Neurosurgery, Vivantes Klinikum Im Friedrichshain, Berlin, Germany.
Acta Neuropathol ; 140(6): 893-906, 2020 12.
Article en En | MEDLINE | ID: mdl-32926213
Paragangliomas/pheochromocytomas are rare neuroendocrine tumors that arise from the adrenal gland or ganglia at various sites throughout the body. They display a remarkable diversity of driver alterations and are associated with germline mutations in up to 40% of the cases. Comprehensive molecular profiling of abdomino-thoracic paragangliomas revealed four molecularly defined and clinically relevant subtypes. Paragangliomas of the cauda equina region are considered to belong to one of the defined molecular subtypes, but a systematic molecular analysis has not yet been performed. In this study, we analyzed genome-wide DNA methylation profiles of 57 cauda equina paragangliomas and show that these tumors are epigenetically distinct from non-spinal paragangliomas and other tumors. In contrast to paragangliomas of other sites, chromosomal imbalances are widely lacking in cauda equina paragangliomas. Furthermore, RNA and DNA exome sequencing revealed that frequent genetic alterations found in non-spinal paragangliomas-including the prognostically relevant SDH mutations-are absent in cauda equina paragangliomas. Histologically, cauda equina paragangliomas show frequently gangliocytic differentiation and strong immunoreactivity to pan-cytokeratin and cytokeratin 18, which is not common in paragangliomas of other sites. None of our cases had a familial paraganglioma syndrome. Tumors rarely recurred (9%) or presented with multiple lesions within the spinal compartment (7%), but did not metastasize outside the CNS. In summary, we show that cauda equina paragangliomas represent a distinct, sporadic tumor entity defined by a unique clinical and morpho-molecular profile.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Paraganglioma / Cauda Equina / Neoplasias del Sistema Nervioso Central / Tumores Neuroendocrinos Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: Acta Neuropathol Año: 2020 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Paraganglioma / Cauda Equina / Neoplasias del Sistema Nervioso Central / Tumores Neuroendocrinos Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: Acta Neuropathol Año: 2020 Tipo del documento: Article País de afiliación: Alemania